Nanobiotix Stock

Nanobiotix Net Income 2024

Nanobiotix Net Income

-48.21 M EUR

Ticker

NANO.PA

ISIN

FR0011341205

WKN

A1J7EB

In 2024, Nanobiotix's profit amounted to -48.21 M EUR, a 21.44% increase from the -39.7 M EUR profit recorded in the previous year.

The Nanobiotix Net Income history

YEARNET INCOME (undefined EUR)
2029e70.49
2028e-26.25
2027e-43.27
2026e-25.79
2025e-50.94
2024e-48.21
2023-39.7
2022-57.04
2021-47
2020-33.59
2019-50.92
2018-30.35
2017-26.14
2016-21.88
2015-17
2014-9.56
2013-8.14
2012-5.33
2011-5.25
2010-4.09
2009-1.51

Nanobiotix Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into Nanobiotix, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Nanobiotix from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Nanobiotix’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Nanobiotix. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Nanobiotix’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Nanobiotix’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Nanobiotix’s growth potential.

Nanobiotix Revenue, EBIT and net profit per share

DateNanobiotix RevenueNanobiotix EBITNanobiotix Net Income
2029e159.4 M undefined0 undefined70.49 M undefined
2028e58.61 M undefined-12.25 M undefined-26.25 M undefined
2027e30.12 M undefined-38.38 M undefined-43.27 M undefined
2026e48.16 M undefined-17.92 M undefined-25.79 M undefined
2025e12.04 M undefined-45.72 M undefined-50.94 M undefined
2024e20.49 M undefined-46.4 M undefined-48.21 M undefined
202330.06 M undefined-26.78 M undefined-39.7 M undefined
20220 undefined-46.7 M undefined-57.04 M undefined
202110,000 undefined-52.58 M undefined-47 M undefined
202050,000 undefined-36.43 M undefined-33.59 M undefined
201968,000 undefined-46.78 M undefined-50.92 M undefined
2018116,000 undefined-30.07 M undefined-30.35 M undefined
2017252,000 undefined-25.27 M undefined-26.14 M undefined
20161.56 M undefined-21.85 M undefined-21.88 M undefined
2015265,540 undefined-17.14 M undefined-17 M undefined
2014967,500 undefined-9.62 M undefined-9.56 M undefined
2013180,000 undefined-8.18 M undefined-8.14 M undefined
201270,000 undefined-5.15 M undefined-5.33 M undefined
20111.36 M undefined-5.23 M undefined-5.25 M undefined
20101.13 M undefined-4.1 M undefined-4.09 M undefined
20092.77 M undefined-1.5 M undefined-1.51 M undefined

Nanobiotix stock margins

The Nanobiotix margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Nanobiotix. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Nanobiotix.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Nanobiotix's sales revenue. A higher gross margin percentage indicates that the Nanobiotix retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Nanobiotix's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Nanobiotix's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Nanobiotix's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Nanobiotix. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Nanobiotix's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Nanobiotix Margin History

Nanobiotix Gross marginNanobiotix Profit marginNanobiotix EBIT marginNanobiotix Profit margin
2029e26,500 %0 %44.22 %
2028e26,500 %-20.91 %-44.79 %
2027e26,500 %-127.43 %-143.67 %
2026e26,500 %-37.2 %-53.54 %
2025e26,500 %-379.83 %-423.2 %
2024e26,500 %-226.43 %-235.28 %
202326,500 %-89.09 %-132.08 %
202226,500 %0 %0 %
202126,500 %-525,790 %-470,030 %
20204,640 %-72,856 %-67,180 %
201926,500 %-68,792.65 %-74,875 %
201826,500 %-25,919.83 %-26,159.48 %
201726,500 %-10,026.59 %-10,374.21 %
201626,500 %-1,402.65 %-1,404.31 %
201526,500 %-6,455.39 %-6,403.21 %
201426,500 %-994.29 %-987.76 %
201326,500 %-4,544.44 %-4,522.22 %
201226,500 %-7,357.14 %-7,614.29 %
2011100 %-384.56 %-386.03 %
2010100 %-362.83 %-361.95 %
200996.39 %-54.15 %-54.51 %

Nanobiotix Aktienanalyse

What does Nanobiotix do?

Nanobiotix SA is a biotechnology company specializing in the development of nanoparticles used in cancer therapy to increase the effectiveness of radiation therapy. It was founded in 2003 in Paris, France by Dr. Laurent Lévy and his team. The company went public in 2012 and is currently listed on the Euronext Paris exchange. Nanobiotix's business model is based on the production and marketing of nanoparticles called NBTXR3, which enhance the effectiveness of radiation therapy. The company works with various partners to further develop its technology and explore new applications. Nanobiotix has two main divisions: one focused on developing nanoparticles to enhance radiation therapy for cancer, and another dedicated to using nanoparticles as drug carriers. Its flagship product, NBTXR3, is designed specifically for cancer therapy and has shown promising results. Nanobiotix is also working on combining NBTXR3 with immunotherapies to further improve cancer treatment. In summary, Nanobiotix is an innovative company specializing in the development of nanoparticles to enhance radiation therapy for cancer and improve patient treatment. Nanobiotix ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Nanobiotix's Profit Margins

The profit margins of Nanobiotix represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Nanobiotix's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Nanobiotix's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Nanobiotix's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Nanobiotix’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Nanobiotix stock

How much profit has Nanobiotix made this year?

Nanobiotix has made -48.21 M EUR this year.

How has the profit developed compared to last year?

The profit has increased by 21.44% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Nanobiotix publish its earnings?

Nanobiotix publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Nanobiotix?

The profits of Nanobiotix are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Nanobiotix?

You can learn more about the earnings of Nanobiotix by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Nanobiotix pay?

Over the past 12 months, Nanobiotix paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Nanobiotix is expected to pay a dividend of 0 EUR.

What is the dividend yield of Nanobiotix?

The current dividend yield of Nanobiotix is .

When does Nanobiotix pay dividends?

Nanobiotix pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Nanobiotix?

Nanobiotix paid dividends every year for the past 0 years.

What is the dividend of Nanobiotix?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nanobiotix located?

Nanobiotix is assigned to the 'Health' sector.

Wann musste ich die Aktien von Nanobiotix kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nanobiotix from 11/17/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 11/17/2024.

When did Nanobiotix pay the last dividend?

The last dividend was paid out on 11/17/2024.

What was the dividend of Nanobiotix in the year 2023?

In the year 2023, Nanobiotix distributed 0 EUR as dividends.

In which currency does Nanobiotix pay out the dividend?

The dividends of Nanobiotix are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Nanobiotix stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Nanobiotix

Our stock analysis for Nanobiotix Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nanobiotix Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.